Pharmazz, Inc.

Pharmazz, Inc. is a privately held biopharmaceutical company headquartered in Willowbrook, Illinois, United States. Founded in 2010 by Professor Dr. Anil Gulati, a pharmacologist, inventor and academic, the company focuses on discovering, acquiring, developing and commercializing novel pharmaceutical products for critical care and hospital settings. Its stated mission is to advance basic research from academic institutions into drug products that address severe, unmet medical needs in critical care medicine. The company's pipeline is built around two first-in-class drug candidates. Sovateltide is being developed for cerebral ischemic stroke and other neurodegenerative disorders, and has received FDA Orphan Drug Designation for the treatment of neonatal hypoxic-ischemic encephalopathy. Centhaquine, marketed under the brand name Lyfaquin, is a resuscitative agent for hypovolemic shock; Pharmazz has described taking centhaquine from bench to bedside in ten years, with market authorization obtained in May 2020 and launch in November 2020. Pharmazz operates through subsidiaries in India (Pharmazz India Private Limited) and the United Kingdom (Pharmazz UK Limited). It has signed licensing agreements with Midwestern University (2011) and The Board of Trustees of the University of Illinois (2014). Clinical development has been conducted in India and, for sovateltide's RESPECT-ETB Phase 3 trial in acute cerebral ischemic stroke, in the United States, United Kingdom, Germany and Spain. The company also sponsors academic research and scientific conferences, including the Nineteenth International Conference on Endothelin (ET-19). As a private, development-stage company, Pharmazz does not disclose public financial results. Its activities center on late-stage clinical trials, regulatory designations and the expansion of its pipeline into additional indications such as acute kidney injury, postpartum hemorrhage, traumatic brain injury, hearing loss and wound healing.

Pharmazz, Inc. was established in 2010 as an emerging global pharmaceutical company focused on discovering, acquiring, developing and marketing novel pharmaceutical products for critical care and hospital settings. It was founded and is led by Professor Dr. Anil Gulati, a pharmacologist, inventor and academic. In January 2011 the company signed a licensing agreement with Midwestern University, and in March 2011 it started its Indian subsidiary, Pharmazz India Private Limited. A further licensing agreement was signed with The Board of Trustees of the University of Illinois in January 2014. The company also established a UK subsidiary, Pharmazz UK Limited. Clinical development of centhaquine for hypovolemic shock began in India, with approval for a Phase I trial obtained in September 2014, followed by Phase II approval in December 2016 and Phase III approval in December 2018. Market authorization was obtained in May 2020 and Lyfaquin was launched in November 2020. Pharmazz has stated that it accomplished centhaquine development from bench to bedside in ten years. Clinical development of sovateltide started in India with a Phase I study in July 2016. Approval for a Phase II trial in India for cerebral ischemic stroke was obtained in August 2017, and for Phase III in July 2019. Permission for Phase II studies of sovateltide in Alzheimer's disease was obtained in August 2017 and in acute spinal cord injury in October 2018. The company later initiated the RESPECT-ETB Phase 3 clinical trial of sovateltide in acute cerebral ischemic stroke, enrolling patients in the United States, United Kingdom, Germany and Spain. It also conducted a Phase II trial of sovateltide in hypoxic-ischemic encephalopathy in neonates and a Phase IV trial in acute cerebral ischemic stroke, and a multi-centric open-labeled study of centhaquine as a resuscitative agent. The FDA granted sovateltide Orphan Drug Designation to treat neonatal hypoxic-ischemic encephalopathy. Pharmazz continues to sponsor research in academic organizations and to analyze preclinical and clinical data to generate new leads, with promising indications in development including acute kidney injury, postpartum hemorrhage, neonatal hypoxic-ischemic encephalopathy, traumatic brain injury, hearing loss and wound healing.

• 2020

  Market authorization for centhaquine obtained in May; Lyfaquin launched in November.

• 2019

  Sovateltide Phase III approval for cerebral ischemic stroke in July.

• 2018

  Centhaquine Phase III approval in December; sovateltide Phase II permission for acute spinal cord injury in October.

• 2017

  Sovateltide Phase II approval for stroke in August; Phase II permission for Alzheimer's disease in August.

• 2016

  Sovateltide Phase I study in July; centhaquine Phase II approval in December.

• 2014

  Licensing agreement with The Board of Trustees of the University of Illinois in January; centhaquine Phase I approval in September.

• 2011

  Licensing agreement with Midwestern University in January; Pharmazz India Private Limited started in March.

• 2010

  Pharmazz, Inc. incorporated in October.

A visionary biopharmaceutical company dedicated to developing and commercializing innovative therapeutics for critical care medicine, focused on novel chemical entities targeting severe, unmet medical needs.

• Sovateltide

  A first-in-class drug candidate for cerebral ischemic stroke and other neurodegenerative disorders; received FDA Orphan Drug Designation for neonatal hypoxic-ischemic encephalopathy.

• Centhaquine (Lyfaquin)

  A resuscitative agent for hypovolemic shock; market authorization obtained in May 2020 and launched in November 2020.

1. 1Pharmazz, Inc. official websitepharmazz.com
2. 2History | Pharmazz, Inc.pharmazz.com
3. 3About Us | Pharmazz, Inc.pharmazz.com
4. 4Upcoming Products | Pharmazz, Inc.pharmazz.com
5. 5Pharmazz, Inc. (United States) - Wikidatawikidata.org